In summary, these data identify MET activation as not only a prognostic marker for poor clinical outcomes but also as a key contributor to the development of an immunosuppressive microenvironment in PDAC through the functional exhaustion of tumor‐infiltrating CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.